Secretary of State Marco Rubio signaled a shift in U.S. vaccine diplomacy during Senate testimony, suggesting the State Department would reassert oversight of America's relationship with Gavi, the international vaccine alliance that works to increase immunization access in lower-income countries.
Rubio's statement represents a rebuke of Robert F. Kennedy Jr., who as head of the Department of Health and Human Services has questioned vaccine safety and pushed to withdraw U.S. funding from global vaccination efforts. The tension between the two officials reflects deeper divisions within the Trump administration over vaccine policy and international health engagement.
Gavi coordinates immunization programs across 78 countries, helping vaccinate children against diseases like measles, polio, and rotavirus. The organization has historically received U.S. government support through multiple agencies, including USAID and the State Department.
Kennedy has promoted vaccine skepticism for decades and advocated for the U.S. to leave the World Health Organization. His appointment to lead HHS sparked concern among public health experts who worry his views could undermine confidence in established vaccines and compromise global immunization efforts.
Rubio's testimony suggests the State Department intends to maintain U.S. participation in Gavi's work, positioning vaccine diplomacy as a foreign policy priority separate from domestic vaccine hesitancy debates. International vaccine alliances like Gavi address disease outbreaks that cross borders and strengthen relationships with partner nations.
The dispute reveals competing visions for American health leadership. Kennedy emphasizes questioning established vaccine guidance and reducing government vaccine programs. Rubio appears focused on preserving traditional U.S. engagement in global health infrastructure.
Public health experts generally support expanded vaccine access globally, noting that infectious diseases respect no borders. Measles, polio, and other vaccine-preventable illnesses pose ongoing threats where immunization coverage remains low.
The outcome of this internal administration disagreement will likely